MELANOMA BRIDGE
December 3rd - December 5th, 2020
VIRTUAL MEETING
December 3rd 2020
MELANOMA BRIDGE OPENING SESSION**
Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov
09.20 PM | Anti-cancer responses to the spectrum of “Cancer Antigens” and immune contraction**, Bernard A. Fox |
09.40 PM | The immune contexture for survival and immunotherapy response**, Jerome Galon |
December 4th 2020
12.30 PM | Introduction and objectives, Paolo A. Ascierto |
Session - Melanoma as a model system
Chairpersons: Giuseppe Masucci, Magdalena Thurin
12.40 PM | Targeting the microbiota in melanoma anti-PD1 therapy, Giorgio Trinchieri |
12.55 PM | Prediction of response to check point inhibition: is there a simple but not simplistic way? Iman Osman |
01.10 PM | Immunotherapy-induced anti-cancer responses, Bernard A. Fox |
01.25 PM | The role of CD39 in melanoma, Michele Teng |
01.40 PM | Discussion on Melanoma as a model system, Giuseppe Masucci, Magdalena Thurin |
01.55 PM | Break ** |
02.25 PM | b Adrenergic Receptors: "A non-canonical Immune Checkpoint?", Marc Ernstoff |
02.40 PM | Escape mechanisms in melanoma, Soldano Ferrone |
02.55 PM | Electrochemotherapy in metastatic melanoma, Corrado Caracò |
03.10 PM | Uveal Melanoma, Richard D. Carvajal |
03.25 PM | Discussion on Melanoma as a model system, Giuseppe Masucci, Magdalena Thurin |
03.40 PM | SYMPOSIUM Target therapy in Melanoma |
The role of target therapies in the treatment of Melanoma Braf positive between present and future, Paul Nathan, Paolo A. Ascierto |
04.30 PM | Break ** |
SESSION 3 MECHANISMS OF RESISTANCE AND DRIVERS OF RESPONSE
Chairpersons: Paolo A. Ascierto, Gerardo Botti, Giuseppe Palmieri
04.45 PM | SYMPOSIUM Adjuvant Therapy |
Adjuvant therapy in melanoma: maximizing the chances for a cure Olivier Michielin, Paolo A. Ascierto |
05.35 PM | Translational research in the metastatic melanoma, Reinhard Dummer |
05.50 PM | Intrinsic tumor genomic and metabolic factors , Patrick Hwu |
06.05 PM | Achieving durable MAPK Suppression and Invigorating Anti-melanoma T Cell Immunity, Roger Lo |
04.30 PM | Break ** |
06.35 PM | Tumor mutation burden and liquid biopsies, Claus Garbe |
06.50 PM | Mechanisms of resistance to cancer immunotherapy, Thomas F. Gajewski |
07.05 PM | T-cell intrinsic mechanisms of resistance to PD1 checkpoint blockade, Michelle Krogsgaard |
07.20 PM | Targeting dendritic cells to enhance the effectiveness of PD1 blockade against cold tumors, Pawel Kalinski |
07.35 PM | Discussion on Mechanisms of resistance and drivers of response, Paolo A. Ascierto, Gerardo Botti, Giuseppe Palmieri |
December 5th 2020
SESSION EMERGENT STRATEGIES
Chairpersons: Alexander M. Eggermont, Alessandro Testori
12.30 AM | SYMPOSIUM IO and adjuvant therapy in melanoma |
Adjuvant immunotherapy in melanoma: current practice and future directions, Georgina V. Long, Paolo A. Ascierto |
01.20 PM | Neoadjuvant Immunotherapy - less is more , Christian Blank |
01.35 PM | What are new ways to think about immunotherapy combinations for melanoma? Michael A. Postow |
01.50 PM | Considering QUAD therapy to address unmet needs in high risk BRAF mutant melanoma, Jason Luke |
02.05 PM | Break ** |
02.20 PM | Development of novel antibodies targeting regulatory T cells in cancer, Sergio Quezada |
02.35 PM | Oncolytic virus combo with CKI- Ipi talimogene laherparepvec and talimogene laherparepvec+Pembrolizumab, Igor Puzanov |
02.50 PM | Exploring the potential of dendritic cell therapy for the treatment of advanced melanoma, from moDC to myDC, Bart Neyns |
03.05 PM | Discussion on Emergent strategies, Alexander M. Eggermont, Alessandro Testori |
03.35 PM | Break ** |
SESSION GREAT DEBATE
Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov
03.50 PM | Is innate immunity important: yes or no? Jeffrey S. Weber, Alexander M. Eggermont |
04.20 PM | Discussion on "Is innate immunity important: yes or no?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
04.30 PM | Does AJCC classification an emprovement for better staging: yes or no? Jeffrey E. Gershenwald, Jean-Jacques Grob |
05.00 PM | Discussion on "Does AJCC classification an emprovement for better staging: yes or no?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
05.10 PM | Break ** |
05.25 PM | Is the sentinel node biopsy useful for staging patient: yes or no? Vernon K. Sondak, Jean-Jacques Grob |
05.55 PM | Discussion on "Is the sentinel node biopsy useful for staging patient: yes or no?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
06.05 PM | Triplette combination (target therapy plus IO) VS combo IO Jeffrey A. Sosman, Michael B. Atkins |
06.35 PM | Discussion on "Triplette combination (target therapy plus IO) VS combo IO" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
06.45 PM | Break ** |
07.00 PM | Neoadjuvant or adjuvant therapy: which is better? Hussein A. Tawbi, Omid Hamid |
07.30 PM | Discussion on "Neoadjuvant or adjuvant therapy: which is better?" Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
07.40 PM | What we will do on Monday? Sanjiv S. Agarwala |
07.55 PM | Conclusions Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
For information please contact info@melanomabridge.org